Developing new small molecules to treat Alzheimer's disease
Development of orally bioavailable and blood-brain barrier penetrant, small molecule TAK1 inhibitors as a novel treatment for Alzheimer's Disease
['FUNDING_OTHER'] · EYDIS BIO, INC. · NIH-11007130
This study is looking for new ways to help people with Alzheimer's by testing special tiny molecules that can reach the brain and target a protein called TAK1, which is linked to memory loss and brain cell damage, with the hope of finding better treatments to improve thinking skills and overall well-being.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EYDIS BIO, INC. (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-11007130 on ClinicalTrials.gov |
What this research studies
This research focuses on creating small molecule inhibitors that can effectively penetrate the blood-brain barrier to target TAK1, a protein involved in the progression of Alzheimer's disease. By investigating the role of TAK1 in cognitive decline and neuronal death, the research aims to identify new therapeutic options that could slow or prevent the disease's progression. The approach includes using patented TAK1 inhibitors and testing their effectiveness in preclinical models of Alzheimer's. Patients may benefit from new treatment options that could improve their cognitive function and quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it.
Not a fit: Patients with other forms of dementia or cognitive decline unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the lives of patients with Alzheimer's disease.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in Alzheimer's disease, indicating potential for success with this novel approach.
Where this research is happening
DURHAM, UNITED STATES
- EYDIS BIO, INC. — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SCARNEO, SCOTT — EYDIS BIO, INC.
- Study coordinator: SCARNEO, SCOTT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome